The first approved synthetic lethal drug, a PARP inhibitor targeting poly ADP‐ribose polymerase (PARP), has demonstrated efficacy against cancer cells with specific genetic mutations, such as BRCA1 or BRCA2 mutations [10]. The gene discussed is BRCA1; the disease is cancer.